Going back to the OP question, my hope for the immediate future:
1) Sell the infusion Business for a good price, this will give the company some breathing space
2) Successful tavr animal trial.
3) Sign a JV tavr agreement with one of the majors with upfront payment hopefully that can goes to general spending funds.
4) long overdue approvals in Australia and Europe.
The above should happen soon, or another CR with dilution to eclipse what we already suffered from.
Expections/thoughts for the future from here on in for retail investors., page-15
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |